首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Research

Cancer Research杂志,由American Association for Cancer Research Inc.出版,于1941年创刊,Semimonthly,出版语言English,ISSN:0008-5472,E-ISSN:1538-7445。

投稿咨询
Cancer Research
Cancer Research
Cancer Research
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
22.6
CiteScore
17
期刊收录
SCI、SCIE

Cancer Research(中文译名:《癌症研究》),ISSN:0008-5472,EISSN:1538-7445,是American Association for Cancer Research Inc.出版的国际性学术期刊,创刊于1941年,以Semimonthly形式稳定发行,2026年总发文量约291篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达22.6,2025年期刊CiteScore为17,2025年期刊自引率约0.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2.5月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Japan、England、GERMANY (FED REP GER)、Canada、France等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMHARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、MEMORIAL SLOAN KETTERING CANCER CENTER、UNICANCER、JOHNS HOPKINS UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 16 / 333

95.3

学科:ONCOLOGY SCIE Q1 22 / 333

93.54

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 16 / 328

95.3

学科:ONCOLOGY SCIE Q1 24 / 328

92.84


中国学者近期发文

1
KH617 API manufacturing: A synthetic biology approac

Author:Zhou, Yi; Liu, Jiong-Qin; Gao, Cheng-Guo; Luo, Hao; Zhao, Man-Xi; Ke, Xiao

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB033-LB033. DOI: 10.1158/1538-7445.AM2026-LB033

2
Cytomegalovirus reactivation orchestrates myeloid reprogramming to drive brain metastasis progressio

Author:Zhao, Hong; Dong, Wenjuan; Xu, Shan; Wang, Shiruo; Puri, Akshjot; Vasquez, Matthew; Gao, Dongbing; Yu, Xiaohui; Cui, Johnny; Lau, Johnson; Sampson, James; Sannes, Caitlin; Chang, Jenny; Wong, Stephen

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB256

3
Preclinical evaluation of a novel orally bioavailable MDM2 PROTAC, NW-8-461, in acute leukemia and myelofibrosi

Author:Zhang, Qinhong; Xu, Yajing; Wu, Qiong; Tu, Cecilia Z.; Wang, Shijia; Yin, Kai; Xu, Xuesong; Zhang, Zhang; Dai, Bing; Tan, Fenlai; Chen, Yi

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB038-LB038. DOI: 10.1158/1538-7445.AM2026-LB038

4
Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumor

Author:Zhang, Jinhui; Deng, Minjuan; Jiang, Bin; Li, Jie; Wang, Judy; Hamilton, Erika; Gao, Hua-Xin; Song, Xiaomin; Shen, Zhirong; Jin, Wei; Donate, Fernando

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-CT121

5
Towards a platform PBPK-QSP model for first-in-human dose selection of GenSci139, a potential best-in-class EGFR×HER2 bispecific ADC, in patients with cance

Author:Zhang, Fan; Xie, Yehua; Ma, Guangli; Liang, Xiao; Zhao, Xumin; Lin, Yihui; Ye, Xuan; Qi, Peng; Wang, Xiaozhen; Zhang, Haizhou; Zhang, Shu; Wang, Siqin; Jin, Lei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB441

6
Whole body PBPK/PD modeling to support first-in-human dose selection for GenSci140, a potential best-in-class FRα biparatopic ADC, in patients with cance

Author:Zhang, Fan; Xie, Yehua; Ma, Guangli; Liang, Xiao; Zhao, Xumin; Lin, Yihui; Ye, Xuan; Qi, Peng; Wang, Xiaozhen; Zhang, Haizhou; Zhang, Shu; Wang, Siqin; Jin, Lei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB442

7
AI guided engineering of pH responsive antibodies enables tumor selective targeting and improves the therapeutic inde

Author:Yu, Qilin; Chen, Mingchen; Lu, Ying; Wang, Yuxi

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB027-LB027. DOI: 10.1158/1538-7445.AM2026-LB027

8
TCE-A: An OR-gate CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune disease

Author:Ying, Hanxiao; Wu, Emily; Duan, Sizhu; Bai, Dongmei; Wang, Jing; Pu, Pu; Zhang, Limin; Wang, Chunyue; Hu, Min; He, Feng

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB270

9
A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death induce

Author:Yao, Herui; Li, Ning; Yu, Henry Ninghui; Massimini, Giorgio; Zhao, Jianli; Wang, Shuhang; Zhao, Yiming; Yu, Yue; Lai, Xiuping; Lv, Xiaozhi; Wang, Shaoshan; Guo, Xia; Huang, Jiancheng; Tan, Fei; Song, Erwei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. CT074-CT074. DOI: 10.1158/1538-7445.AM2026-CT074

10
Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NH

Author:Xu, Jun; Meng, Qingyuan; Liao, Yuting; Zhang, Chen; Wei, Jing; Tang, Ruofeng; Dou, Caixia; Yang, Jie; Tang, Pingming; Chen, Zhen; Lu, Yao; Wang, Ju; Yan, Pangke

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB039-LB039. DOI: 10.1158/1538-7445.AM2026-LB039


在线咨询

Cancer Research

国际简称:CANCER RES参考译名:癌症研究

年发文量:291 CiteScore:17 是否预警:否 Gold OA文章占比:35.17% 研究类文章占比:93.47%

杂志社联系方式:AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404

Cancer Research